Synoptic Bio, PBC
Proteomics-Powered
Preventive Health
Early disease detection through proteomics. Explore our science, strategy, and financials below — interactive dashboards are live; documents marked In preparation are being finalised.
Corporate & Governance
5 documents
Cap Table
Carta export · 409A valuation included
Certificate of Incorporation
Delaware PBC
Bylaws
Board Consents & Resolutions
SAFE / Convertible Note Terms
Seed round instrument
Team
2 interactive
Team
Team & Org Chart
Founder bio, seed-stage team structure, candidate profiles, and reporting lines — with planned post-seed roles.
Hiring
Founding CEO
✓ Hired
CBO
CMO
Head of DS
Project Mgr.
Talent Pipeline
Founding team recruiting tracker — 8 roles, 26 candidates, pipeline status, job descriptions, and warm-list contacts.
Science & Technology
2 interactive · 3 documents
R&D
R&D Dashboard
Full programme management — 4 projects, milestones, study arms, budgets, contacts, deliverables, and live editing.
Atlas
Biomarker Atlas
Searchable reference of 100+ validated and candidate protein biomarkers — AUC data, study populations, replication status, citations.
Key Publications & Preprints
INTEGRAL validation — Olink proteomics lung cancer detection
Platform White Papers
Proteomics platform overview, assay design, and clinical utility rationale
Method Documentation & Lab Notebooks
SOP-level validation detail; shared on specific request only
Intellectual Property
4 documents
Patent Filings — Provisional & Non-Provisional
Lung cancer protein signature; sample type method claims
Freedom-to-Operate (FTO) Analysis
Landscape review across protein biomarker and proteomics method claims
License Agreements (In / Out)
Foundation-mediated IARC license; any outbound licenses
Invention Assignment Agreements
Market & Commercial
2 interactive · 2 documents
Competitive
Competitor Tracker
10 competitors tracked — modality, clinical stage, sensitivity/specificity benchmarks, funding, and threat assessment with events log.
Market
Market Opportunity
Three converging markets: clinical diagnostics ($5B→$10B), DTC molecular health ($8B→$20B), and the $100B+ population-scale preventive health convergence.
Letters of Intent & Pilot MOUs
23andMe distribution agreement; clinical site access MOUs
KOL & Advisor Board
Named scientific and clinical advisors; engagement terms
Financial
2 interactive
Legal
3 documents
Material Contracts
Data access agreements, platform licences
Vendor & CRO Agreements
IARC, biobank, laboratory service agreements
Advisor & Key Employment Agreements
Advisor agreements, founder equity, pre-funding commitments